Skip to Main content Skip to Navigation
Journal articles

Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.

Abstract : Gemcitabine-containing regimens are among standard therapies for the treatment of advanced non-small cell lung,pancreatic, or bladder cancers. Gemcitabine is a nucleoside analogue and its cytotoxicity is correlated with incorporation into genomic DNA and concomitant inhibition of DNA synthesis. However, it is still unclear by which mechanism(s) gemcitabine incorporation leads to cell death.
Document type :
Journal articles
Complete list of metadata
Contributor : Philippe Pourquier Connect in order to contact the contributor
Submitted on : Tuesday, January 14, 2020 - 10:54:27 AM
Last modification on : Wednesday, May 26, 2021 - 7:56:03 PM


  • HAL Id : inserm-02438313, version 1
  • PUBMED : 12171875



Philippe Pourquier, Christopher Gioffre, Glenda Kohlhagen, yoshimasa Urasaki, François Goldwasser, et al.. Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.. Clinical Cancer Research, American Association for Cancer Research, 2002, 8 (8), pp.2499-504. ⟨inserm-02438313⟩



Record views